Orient Pharma CoROCO:4166 +5.02%56 Piotroski F-Score is 8 as of Jul. 07, 2026, which is 300% above its 10-year median of 2.00. GuruFocus rates ROCO:4166 with a GF Score™ of 56/100 and a GF Value™ of NT$45.09 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 981 Drug Manufacturers companies, Orient Pharma Co ranks better than 98.37% on this metric.
Good Sign:
Piotroski F-Score is 8, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Orient Pharma Co has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for Orient Pharma Co's Piotroski F-Score or its related term are showing as below:
ROCO:4166'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 2 Max: 9
Current: 8
During the past 13 years, the highest Piotroski F-Score of Orient Pharma Co was 9. The lowest was 1. And the median was 2.
Orient Pharma Co (ROCO:4166) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Orient Pharma Co Piotroski F-Score Related Terms
Orient Pharma Co Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Orient Pharma Co's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4166 vs ZTS, UTHR: Piotroski F-Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orient Pharma Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orient Pharma Co Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orient Pharma Co's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Orient Pharma Co's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Dec25) TTM:
Last Year (Dec24) TTM:
Net Income was 50.571 + 18.774 + 47.264 + 91.829 = NT$208 Mil. Cash Flow from Operations was 126.306 + 68.943 + 63.596 + 101.013 = NT$360 Mil. Revenue was 316.902 + 325.546 + 316.122 + 441.808 = NT$1,400 Mil. Gross Profit was 165.222 + 183.573 + 176.412 + 265.514 = NT$791 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was
(2520.582 + 2537.089 + 2550.174 + 2887.108 + 2938.353) / 5 = NT$2686.6612 Mil. Total Assets at the begining of this year (Dec24) was NT$2,521 Mil. Long-Term Debt & Capital Lease Obligation was NT$180 Mil. Total Current Assets was NT$1,259 Mil. Total Current Liabilities was NT$187 Mil.
Net Income was 38.008 + 59.003 + -1.018 + 11.381 = NT$107 Mil.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Orient Pharma Co's current Net Income (TTM) was 208.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Orient Pharma Co's return on assets of this year was 0.08269439. Orient Pharma Co's return on assets of last year was 0.0418992.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Orient Pharma Co's gearing of this year was 0.06692805. Orient Pharma Co's gearing of last year was 0.09291914.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Orient Pharma Co's current ratio of this year was 6.72975949. Orient Pharma Co's current ratio of last year was 1.49497383.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Orient Pharma Co's number of shares in issue this year was 248.984. Orient Pharma Co's number of shares in issue last year was 223.035.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Orient Pharma Co's gross margin of this year was 0.56464826. Orient Pharma Co's gross margin of last year was 0.53283487.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Orient Pharma Co's asset turnover of this year was 0.55557724. Orient Pharma Co's asset turnover of last year was 0.47716409.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
1
+
1
+
1
+
0
+
1
+
1
=
8
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Orient Pharma Co has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.
Orient Pharma Co (ROCO:4166) has a Piotroski F-Score of 8 as of Jul. 07, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Orient Pharma Co and its competitors. This is 300% above median its historical median of 2.00. Over the past decade, Orient Pharma Co's Piotroski F-Score has ranged from 1.00 to 9.00. According to the industry distribution chart, Orient Pharma Co ranks #16 out of 981 companies in the Drug Manufacturers industry, placing it in the top 1.6%.
Is Orient Pharma Co's Piotroski F-Score too high?
Orient Pharma Co's current Piotroski F-Score of 8 is 300% above median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 9.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Orient Pharma Co's value of 8 is 60% above this industry median. Based on the distribution chart, Orient Pharma Co ranks #16 out of 981 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Orient Pharma Co has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orient Pharma Co's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orient Pharma Co ranks #16 out of 981 companies for Piotroski F-Score. This places Orient Pharma Co in the top 2% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Orient Pharma Co's value of 8 is 60% above this benchmark. Historically, Orient Pharma Co's own Piotroski F-Score has ranged from 1.00 to 9.00 over the past decade. While the company's 10-year median is 2.00 vs. the industry median of 5.00, Orient Pharma Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orient Pharma Co's current Piotroski F-Score of 8 is 60% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Orient Pharma Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orient Pharma Co's current Piotroski F-Score is 8, which is 300% above median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Pharma Co (ROCO:4166) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$45.09, compared to a current price of NT$27.20 — trading 39.7% below its estimated fair value. The current Piotroski F-Score is 8, which is 300% above median its 10-year median of 2.00 and 60% above the Drug Manufacturers industry median of 5.00. Orient Pharma Co's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Orient Pharma Co (ROCO:4166), the current Piotroski F-Score is 8 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orient Pharma Co (ROCO:4166) Overvalued in 2026?
Based on GuruFocus' analysis, Orient Pharma Co stock appears to be undervalued.
The current stock price of NT$27.20 is trading 39.7% below its estimated GF Value™ of NT$45.09.
GuruFocus considers Orient Pharma Co to be Significantly Undervalued.
Key valuation signals for ROCO:4166:
Piotroski F-Score: 8 (300% above median its 10-year median of 2.00)
GF Value™: NT$45.09 vs. price of NT$27.20 (39.7% below fair value)
Industry Position: 60% above the Drug Manufacturers median (#16 of 981)
No single metric tells the full story. See the ROCO:4166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.
56GF Score
Get the complete analysis for ROCO:4166
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4166 has been successfully added to your 
